Latest Ratios: P/E Ratio 19.2x · EV/EBITDA 12.5x · ROE 11.6%. (1996–2025 historical series)
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $8.1B | $9.4B | $10.0B | $10.0B | $11.8B | $13.3B | $12.7B | $7.9B | $8.5B | $7.6B | $7.1B |
| Enterprise Value | $8.9B | $10.2B | $11.0B | $11.0B | $13.1B | $14.5B | $14.1B | $9.0B | $9.5B | $8.7B | $7.7B |
| P/E Ratio → | 19.19 | 22.04 | 120.53 | 27.91 | 25.80 | 23.86 | 175.13 | — | 44.55 | 192.94 | 88.14 |
| P/S Ratio | 3.86 | 4.47 | 5.06 | 5.10 | 5.51 | 5.89 | 6.81 | 5.16 | 5.68 | 5.39 | 5.31 |
| P/B Ratio | 2.15 | 2.47 | 2.80 | 2.63 | 3.41 | 4.28 | 4.55 | 3.11 | 3.24 | 3.01 | 2.72 |
| P/FCF | 17.81 | 20.63 | 19.76 | 33.76 | 20.86 | 30.67 | 67.71 | 140.89 | 40.86 | 47.07 | 28.67 |
| P/OCF | 12.34 | 14.29 | 14.86 | 21.80 | 16.50 | 20.76 | 25.86 | 23.83 | 23.72 | 26.65 | 20.78 |
P/E links to full P/E history page with 30-year chart
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | 4.86 | 5.54 | 5.62 | 6.12 | 6.44 | 7.53 | 5.89 | 6.34 | 6.16 | 5.78 |
| EV / EBITDA | 12.45 | 14.24 | 36.39 | 17.94 | 17.71 | 17.16 | 23.81 | 43.76 | 20.12 | 23.61 | 24.81 |
| EV / EBIT | 17.09 | 19.42 | 66.38 | 22.84 | 22.94 | 21.32 | 27.56 | — | 32.48 | 53.22 | 80.67 |
| EV / FCF | — | 22.43 | 21.63 | 37.21 | 23.15 | 33.53 | 74.88 | 160.57 | 45.60 | 53.78 | 31.24 |
Margins and return-on-capital ratios measuring operating efficiency
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 61.8% | 61.8% | 48.9% | 62.8% | 64.7% | 64.4% | 65.9% | 65.9% | 66.6% | 65.1% | 63.1% |
| Operating Margin | 24.9% | 24.9% | 4.9% | 20.9% | 24.8% | 28.0% | 20.7% | -1.7% | 17.8% | 10.8% | 7.4% |
| Net Profit Margin | 20.3% | 20.3% | 4.2% | 17.4% | 19.8% | 22.8% | 19.2% | -2.7% | 12.7% | 2.8% | 6.0% |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | 11.6% | 11.6% | 2.3% | 9.4% | 12.9% | 17.4% | 13.5% | -1.6% | 7.4% | 1.6% | 3.1% |
| ROA | 7.1% | 7.1% | 1.4% | 5.5% | 6.8% | 8.5% | 6.5% | -0.8% | 3.5% | 0.9% | 1.9% |
| ROIC | 8.6% | 8.6% | 1.6% | 6.4% | 8.8% | 11.1% | 7.4% | -0.5% | 5.5% | 3.3% | 2.3% |
| ROCE | 9.5% | 9.5% | 1.9% | 7.9% | 10.7% | 12.7% | 8.1% | -0.6% | 5.6% | 3.5% | 2.5% |
Solvency and debt-coverage ratios — lower is generally safer
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.44 | 0.44 | 0.45 | 0.44 | 0.58 | 0.68 | 0.70 | 0.68 | 0.83 | 0.70 | 0.41 |
| Debt / EBITDA | 2.32 | 2.32 | 5.35 | 2.75 | 2.74 | 2.51 | 3.29 | 8.40 | 4.60 | 4.78 | 3.46 |
| Net Debt / Equity | — | 0.22 | 0.27 | 0.27 | 0.37 | 0.40 | 0.48 | 0.43 | 0.38 | 0.43 | 0.24 |
| Net Debt / EBITDA | 1.14 | 1.14 | 3.14 | 1.66 | 1.75 | 1.46 | 2.28 | 5.36 | 2.09 | 2.94 | 2.05 |
| Debt / FCF | — | 1.80 | 1.87 | 3.45 | 2.29 | 2.86 | 7.17 | 19.68 | 4.74 | 6.71 | 2.58 |
| Interest Coverage | 15.74 | 15.74 | 3.76 | 9.05 | 9.78 | 12.49 | 7.16 | -0.05 | 4.35 | 3.30 | 2.46 |
Short-term solvency ratios and asset-utilisation metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 3.90 | 3.90 | 3.61 | 1.99 | 2.46 | 1.39 | 2.84 | 1.65 | 2.22 | 5.07 | 3.36 |
| Quick Ratio | 3.31 | 3.31 | 3.09 | 1.62 | 2.09 | 1.17 | 2.33 | 1.47 | 2.05 | 4.59 | 2.92 |
| Cash Ratio | 2.15 | 2.15 | 2.12 | 0.98 | 1.46 | 0.70 | 1.25 | 0.79 | 1.46 | 3.20 | 1.73 |
| Asset Turnover | — | 0.33 | 0.35 | 0.32 | 0.34 | 0.37 | 0.32 | 0.29 | 0.26 | 0.28 | 0.31 |
| Inventory Turnover | 2.65 | 2.65 | 3.62 | 1.84 | 2.11 | 2.45 | 2.19 | 3.05 | 3.07 | 3.17 | 3.61 |
| Days Sales Outstanding | — | 70.31 | 84.69 | 95.77 | 73.98 | 76.13 | 94.96 | 115.88 | 96.65 | 99.42 | 89.46 |
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | 0.7% | 0.6% | — | — | — | — | — | — | — | — | — |
| Payout Ratio | 12.8% | 12.8% | — | — | — | — | — | — | — | — | — |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | 5.2% | 4.5% | 0.8% | 3.6% | 3.9% | 4.2% | 0.6% | — | 2.2% | 0.5% | 1.1% |
| FCF Yield | 5.6% | 4.8% | 5.1% | 3.0% | 4.8% | 3.3% | 1.5% | 0.7% | 2.4% | 2.1% | 3.5% |
| Buyback Yield | 3.8% | 3.3% | 2.9% | 0.2% | 0.2% | 0.8% | 0.5% | 0.9% | 1.2% | 0.8% | 0.0% |
| Total Shareholder Yield | 4.5% | 3.9% | 2.9% | 0.2% | 0.2% | 0.8% | 0.5% | 0.9% | 1.2% | 0.8% | 0.0% |
| Shares Outstanding | — | $208M | $218M | $217M | $223M | $225M | $227M | $220M | $233M | $233M | $230M |
Diagnostic market share erosion
Based on current market data, QGEN trades at a forward P/E of 16.21, which appears to discount the company's historical growth premiums and suggests that investors are pricing in a period of sustained top-line stagnation relative to its diversified life science tools and diagnostic peers.
The current PEG ratio of 0.43 indicates that the market may be undervaluing the company's earnings potential, though this is likely a reflection of skepticism regarding the sustainability of its core diagnostic pillars. Compared to peers like Illumina, which command significantly higher multiples, QGEN's valuation suggests a market perception of limited long-term scalability.
As reported in recent financial statements, QGEN's ROIC has hovered near 2.0% in 2026Q1, a figure that remains structurally low and indicates that the company is struggling to generate returns on invested capital that meaningfully exceed its cost of capital in the current post-pandemic environment.
The persistent gap between ROIC and historical benchmarks suggests that the company's aggressive acquisition strategy has yet to yield the expected synergies. Investors should monitor whether the integration of recent technology pillars can drive a recovery in capital efficiency or if the asset base remains bloated by underperforming intangible assets.
According to quarterly filings, QGEN's cash conversion cycle reached 188 days in 2026Q1, a significant duration that highlights the company's reliance on high inventory levels and suggests potential inefficiencies in managing its global supply chain for specialized diagnostic consumables and automated instrument components.
The elevated days inventory outstanding, which stood at 151 days in the most recent quarter, indicates that the company is carrying substantial stock to mitigate supply chain risks. This working capital intensity acts as a drag on free cash flow, limiting the company's ability to optimize its cash position.
Based on reported figures, QGEN maintains a debt-to-equity ratio of 0.49 as of 2026Q1, a disciplined level that provides the company with significant financial flexibility to navigate sector-specific downturns without the immediate pressure of refinancing or restrictive debt covenants that often constrain more leveraged diagnostic competitors.
The interest coverage ratio of 8.77 remains adequate, suggesting that debt service obligations are well-covered by current operating income. This conservative balance sheet structure serves as a defensive moat, allowing management to pursue strategic M&A or share repurchases even as organic growth faces normalization headwinds.
The P/E ratio is frequently misapplied to QGEN, as it obscures the significant impact of non-cash amortization charges related to past acquisitions and the volatility of COVID-19-related revenue, which together distort the company's true underlying earning power and cash-generating capacity in the eyes of many retail investors.
Analysts should instead prioritize EV/EBITDA or P/FCF to better capture the company's operational performance and cash flow generation. Relying solely on P/E risks misinterpreting the company's valuation by failing to account for the high-margin, recurring nature of its consumable-heavy business model.
Includes 30+ ratios · 30 years · Updated daily
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
See how regular investing compounds over time.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying QGEN stock.
Qiagen N.V.'s current P/E ratio is 19.2x. The historical average is 62.3x.
Qiagen N.V.'s current EV/EBITDA is 12.5x. This enterprise value multiple compares the company's total value (equity + debt - cash) to its EBITDA. The historical average is 30.3x.
Qiagen N.V.'s return on equity (ROE) is 11.6%. The historical average is 9.9%.
Based on historical data, Qiagen N.V. is trading at a P/E of 19.2x. Compare with industry peers and growth rates for a complete picture.
Qiagen N.V.'s current dividend yield is 0.67% with a payout ratio of 12.8%.
Qiagen N.V. has 61.8% gross margin and 24.9% operating margin. Operating margin above 20% indicates strong pricing power and cost efficiency.
Qiagen N.V.'s Debt/EBITDA ratio is 2.3x, indicating moderate leverage. A ratio between 2-4x is manageable but warrants monitoring.